Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110042/S213

S-ICD Electrode Model: 3501

BOSTON SCIENTIFIC CORPORATION · Decision date Jun 3, 2026

FDA DECISIONP110042/S213

What did the FDA decide?

FDA records P110042/S213 as a supplement to PMA P110042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 3, 2026.

FDA approval order statement

the addition of a new controlled environment area (CEA) at the Boston Scientific Dorado, Puerto Rico facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110042/S213
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
OK30
Decision date
Jun 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P110042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110042 · Original PMA

    SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM

  2. P110042/S205 · Related supplement

    SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM

  3. P110042/S206 · Related supplement

    A209 SICD Gen 2,A219 SICD MRI

  4. P110042/S204 · Related supplement

    Subcutaneous Implantable Cardioverter Defibrillator (S-ICD): EMBLEM S-ICD Model A209 and EMBLEM MRI S-ICD Model A219

  5. P110042/S208 · Related supplement

    EMBLEM S-ICD/ model 3501

  6. P110042/S203 · Related supplement

    EMBLEM S-ICD Electrode (Lead)

  7. P110042/S207 · Related supplement

    EMBLEM S-ICD subcutaneous electrode/lead

  8. P110042/S209 · Related supplement

    EMBLEM S-ICD subcutaneous electrode/lead

  9. P110042/S213 received

    Application receipt date recorded by FDA.

  10. P110042/S213 · FDA decision

    30-Day Notice

  11. P110042/S214 · Related supplement

    Emblem S-ICD (A209); Emblem MRI S-ICD (A219)

  12. P110042/S210 · Related supplement

    EMBLEM S-ICD Electrode (Lead) Model 3501

  13. P110042/S215 · Related supplement

    S-ICD EMBLEM GEN 2 (A209); S-ICD EMBLEM MRI (A219)

  14. P110042/S216 · Related supplement

    EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor

Timeline entries are records held by MedtechLedger for P110042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110042

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA approvalSep 28, 2012FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementSep 16, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 22, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJan 8, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 13, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 20, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 20, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMar 6, 2026FDA
EMBLEM, EMBLEM MRIP110042/S212
BOSTON SCIENTIFIC CORPORATIONPMA supplementJun 3, 2026FDA
EMBLEM S-ICDP110042/S211
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 1, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 1, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 7, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 23, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 2, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records